AR066873A1 - Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas - Google Patents
Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR066873A1 AR066873A1 ARP080102391A ARP080102391A AR066873A1 AR 066873 A1 AR066873 A1 AR 066873A1 AR P080102391 A ARP080102391 A AR P080102391A AR P080102391 A ARP080102391 A AR P080102391A AR 066873 A1 AR066873 A1 AR 066873A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- branched
- straight
- atom
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000004434 sulfur atom Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000002541 furyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001544 thienyl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- -1 methylenedioxy group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Abstract
Reivindicacion 1: Los compuestos de la formula general (1): caracterizados porque: R1 representa un átomo de hidrogeno o un grupo alquilo C1-4 recto o ramificado; R2 representa un átomo de hidrogeno o un grupo alquilo C1-4 recto o ramificado; R3 representa un átomo de hidrogeno o un grupo alquilo C1-4 recto o ramificado, o un grupo cicloalquilo C3-6; o un grupo fenilo o tienilo o furilo, opcionalmente substituido con uno o más, idénticos o diferentes, entre grupo alquilo C1-4 recto o ramificado, un grupo alcoxi C1-4 recto o ramificado, un grupo hidroxilo o un átomo de halogeno, o un anillo heterocíclico de 5 o 6 miembros que contiene uno o dos o tres átomos de nitrogeno, o un anillo heterocíclico de 5 miembros que contiene un átomo de nitrogeno y un átomo de oxígeno, o un átomo de nitrogeno y un átomo de azufre, opcionalmente substituido con uno o más, idénticos o diferentes, entre un grupo alquilo C1-4 recto o ramificado, un grupo alcoxi C1-4 recto o ramificado, un grupo hidroxilo o un átomo de halogeno; R4 representa un grupo fenilo, bencilo, tienilo o furilo, opcionalmente substituido con un grupo metilenodioxi, o con uno o más, idénticos o diferentes, entre un grupo alquilo C1-4 recto o ramificado, un grupo alcoxi C1-4 recto o ramificado, un grupo hidroxilo, un grupo trifluorometilo, un grupo ciano, o un átomo de halogeno, o un anillo heterocíclico de 5 o 6 miembros que contiene uno o dos o tres o cuatro átomos de nitrogeno, o un átomo de nitrogeno y un átomo de oxígeno, o un átomo de nitrogeno y un átomo de azufre, opcionalmente substituido con uno o más, idénticos o diferentes, entre un grupo alquilo C1-4 recto o ramificado, un grupo alcoxi C1-4 recto o ramificado, o un átomo de halogeno, o un grupo de la formula general (2) en donde :R6 y R7, independientemente, representan un átomo de hidrogeno, un grupo cicloalquilo C3-6 o un grupo bencilo, o un grupo alquilo C1-4 recto o ramificado, opcionalmente substituido con un grupo amino, un grupo amino substituido con uno o dos, idénticos o diferentes, entre un grupo alquilo C1-4 recto o ramificado, un grupo hidroxilo, un grupo carboxilo o un grupo alcoxi C1-4 recto o ramificado, o, un grupo de la formula general (3), en donde: R8 y R9, independientemente, representan un grupo alquilo C1-4 recto o ramificado, un grupo cicloalquilo C3-6, o un grupo hidroxilo; Z significa un átomo de oxígeno, un átomo de azufre, un grupo -CHR11- o un grupo -NR12-, en donde R11 y R12, independientemente representan un átomo de hidrogeno, un grupo alquilo C1-4 recto o ramificado, un grupo cicloalquilo C3-6, un grupo bencilo, o un grupo -CH2- (acilo C1-5 recto o ramificado), un grupo -CH2-CH2-O-(alquilo C1-4 recto o ramificado) o un grupo acilo C1-5 recto o ramificado; W significa un átomo de nitrogeno o un grupo -CH-; m es un valor de 1, 2, o 3; o es un valor de 1, 2 o 3; p es un valor de cero o 1; r es un valor de cero o 1; t es un valor de cero o 1; R5 representa un átomo de hidrogeno, un grupo alquilo C1-4 recto o ramificado, o un grupo fenilo, bencilo, tienilo o furilo, opcionalmente substituido con un grupo metilenodioxi, o con uno o más, idénticos o diferentes, entre un grupo alquilo C1-4 recto o ramificado, un grupo alcoxi C1-4 recto o ramificado, un grupo hidroxilo, un grupo trifluorometilo, un grupo ciano, o un átomo de halogeno, o un anillo heterocíclico de 5 o 6 miembros que contiene uno o dos o tres o cuatro átomos de nitrogeno, o un átomo de nitrogeno y un átomo de oxigeno, o un átomo de nitrogeno y un átomo de azufre, opcionalmente substituido con uno o más, idénticos o diferentes, entre un grupo alquilo C1-4 recto o ramificado, un grupo alcoxi C1-4 recto o ramificado, un grupo hidroxilo o un átomo de halogeno; R13 representa un grupo ciano, un grupo aminocarbonilo, un grupo -CO-O-(alquilo C1-4 recto o ramificado) o un grupo carboxilo; X significa un grupo -CH2-, un grupo -NH-, un grupo -NR10-, o un átomo de azufre, o un átomo de oxígeno, o un grupo -SO- o -SO2-, en donde R10 representa un grupo alquilo C1-4 recto o ramificado o un grupo cicloalquilo C3-6; n es un valor de cero, 1 o 2; y sus sales, solvatos, N-oxidos e isomeros, así como también las sales y solvatos de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0700395A HUP0700395A2 (en) | 2007-06-07 | 2007-06-07 | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066873A1 true AR066873A1 (es) | 2009-09-16 |
Family
ID=89987565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102391A AR066873A1 (es) | 2007-06-07 | 2008-06-05 | Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas |
Country Status (45)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2641906B1 (en) | 2009-07-08 | 2015-04-22 | Dermira (Canada), Inc. | Tofa analogs useful in treating dermatological disorders or conditions |
FR3053968A1 (fr) | 2016-07-13 | 2018-01-19 | Biomerieux | Reactifs pour la protection reversible de molecules biologiques |
CN109069502B (zh) * | 2016-09-24 | 2021-08-06 | 山东亨利医药科技有限责任公司 | 含盐皮质激素受体拮抗剂的药物组合物及其用途 |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
GR76063B (es) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
ZA836701B (en) * | 1982-10-01 | 1984-10-31 | Roussel Uclaf | Imidazo(1,2-a)quinolines |
GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
BR0209719A (pt) * | 2001-05-31 | 2004-07-27 | Sanofi Synthelabo | Derivados de aminoquinolina e aminopiridina e seu uso como ligandos de adenosina a3 |
US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
CA2471087A1 (en) | 2001-12-21 | 2003-07-03 | Jsw-Research Forschungslabor Gmbh | Pyrazolyl-substituted triazoloquinoxalines |
HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
KR20060065662A (ko) * | 2003-07-31 | 2006-06-14 | 사노피-아벤티스 | 아미노퀴놀린 유도체 및 아데노신 a3 리간드로서의 이의용도 |
-
2007
- 2007-06-07 HU HU0700395A patent/HUP0700395A2/hu unknown
-
2008
- 2008-02-06 UA UAA200913976A patent/UA99463C2/ru unknown
- 2008-06-02 PL PL08762666T patent/PL2167470T3/pl unknown
- 2008-06-02 AU AU2008259534A patent/AU2008259534B2/en not_active Ceased
- 2008-06-02 MY MYPI20095180A patent/MY148654A/en unknown
- 2008-06-02 DE DE602008005589T patent/DE602008005589D1/de active Active
- 2008-06-02 BR BRPI0812257-1A2A patent/BRPI0812257A2/pt not_active IP Right Cessation
- 2008-06-02 SI SI200830255T patent/SI2167470T1/sl unknown
- 2008-06-02 KR KR1020107000342A patent/KR20100031610A/ko not_active Application Discontinuation
- 2008-06-02 WO PCT/HU2008/000063 patent/WO2008149168A1/en active Application Filing
- 2008-06-02 PT PT08762666T patent/PT2167470E/pt unknown
- 2008-06-02 ME MEP-2009-340A patent/ME00958B/me unknown
- 2008-06-02 MX MX2009013209A patent/MX2009013209A/es active IP Right Grant
- 2008-06-02 EP EP08762666A patent/EP2167470B1/en active Active
- 2008-06-02 DK DK08762666.9T patent/DK2167470T3/da active
- 2008-06-02 RU RU2009149518/04A patent/RU2489432C2/ru not_active IP Right Cessation
- 2008-06-02 ES ES08762666T patent/ES2363672T3/es active Active
- 2008-06-02 AT AT08762666T patent/ATE502016T1/de active
- 2008-06-02 NZ NZ581186A patent/NZ581186A/en not_active IP Right Cessation
- 2008-06-02 JP JP2010510891A patent/JP5487100B2/ja not_active Expired - Fee Related
- 2008-06-02 CN CN2008800191923A patent/CN101679272B/zh not_active Expired - Fee Related
- 2008-06-02 CA CA002689612A patent/CA2689612A1/en not_active Abandoned
- 2008-06-05 CL CL200801648A patent/CL2008001648A1/es unknown
- 2008-06-05 PE PE2008000960A patent/PE20090325A1/es not_active Application Discontinuation
- 2008-06-05 PA PA20088782901A patent/PA8782901A1/es unknown
- 2008-06-05 AR ARP080102391A patent/AR066873A1/es not_active Application Discontinuation
- 2008-06-05 JO JO2008263A patent/JO2689B1/en active
- 2008-06-06 UY UY31130A patent/UY31130A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121025A patent/TWI424998B/zh not_active IP Right Cessation
-
2009
- 2009-11-13 TN TNP2009000482A patent/TN2009000482A1/fr unknown
- 2009-11-20 GT GT200900301A patent/GT200900301A/es unknown
- 2009-11-23 ZA ZA2009/08280A patent/ZA200908280B/en unknown
- 2009-11-24 SV SV2009003420A patent/SV2009003420A/es unknown
- 2009-12-02 IL IL202471A patent/IL202471A0/en unknown
- 2009-12-03 NI NI200900210A patent/NI200900210A/es unknown
- 2009-12-04 EC EC2009009783A patent/ECSP099783A/es unknown
- 2009-12-04 DO DO2009000276A patent/DOP2009000276A/es unknown
- 2009-12-04 US US12/631,139 patent/US8338411B2/en active Active
- 2009-12-04 HN HN2009003357A patent/HN2009003357A/es unknown
- 2009-12-16 CR CR11171A patent/CR11171A/es unknown
-
2010
- 2010-01-06 CO CO10001036A patent/CO6270233A2/es active IP Right Grant
- 2010-01-07 MA MA32498A patent/MA31738B1/fr unknown
- 2010-04-29 HK HK10104249.9A patent/HK1138581A1/xx not_active IP Right Cessation
-
2011
- 2011-05-06 HR HR20110332T patent/HRP20110332T1/hr unknown
- 2011-05-30 CY CY20111100519T patent/CY1111644T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066873A1 (es) | Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
AR018187A1 (es) | Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos | |
CO5690577A2 (es) | Derivados de imidazoquinolina como ligandos receptores de adenosina a3 | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
RS51743B (en) | MACROCYCLIC HEPATITIS VIRUS INHIBITORS C | |
AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
AR067562A1 (es) | Compuestos heterociclicos inhibidores de kinasa | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
HRP20070584T3 (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
NI201000011A (es) | Derivados de pirimidina 934. | |
AR066606A1 (es) | Compuestos de heteroarilamida pirimidona | |
NI201200095A (es) | Derivados de piridino - piridinonas, su preparación y su aplicación en terapéutica | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
AR075892A1 (es) | Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
AR066605A1 (es) | Derivados de heteroarilamida pirimidona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |